Leigh Brody
Investment Manager at AlbionVC
London, England
Overview
Work Experience
Investment Manager, UCL Technology Fund
2021 - Current
The UCL Technology Fund is managed by AlbionVC and is dedicated to investing in the next generation of life-changing innovative technologies, arising from UCL's world-class research base.
Board Director
2022
Bloomsbury Genetic Therapies is a spin-out from University College London (UCL), emerging from the world-leading gene therapy and rare diseases expertise of our academic founders, Prof Paul Gissen, Prof Manju Kurian, Prof Ahad Rahim and Prof Simon Waddington, in collaboration with UCL Business. It's mission is bringing potentially curative treatments to patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies.
Member and Angel Investor
2022
Executive Director of Platform Strategy
2019 - 2020
Chief Scientific Officer
2017 - 2019
Director of Genomics
2015 - 2017
Founder
2012 - 2014
Founder of a spin-out from my PhD, developing lipid-based nanoparticles (LNPs) for small molecule and mRNA delivery solutions.
Life Science Investor
2013 - 2014
Index Ventures is a venture capital firm that helps the entrepreneurs turn bold ideas into global businesses.
Research Technician II
2005 - 2008
The RNAi Consortium (TRC) - TRC1, 1.5, 2 and Project Achilles.